GALMED PHARMACEUTICALS LTD. Retained Earnings
GALMED PHARMACEUTICALS LTD. (GLMD) had Retained Earnings of -$215.41 million as of 2026-06-30, per its 6-K filed 2026-09-02.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-09-02
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$215.41M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$210.78M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$205.96M.
- 2025-06-30: Retained Earnings (Accumulated Deficit) -$204.07M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$215.41M 6-K · filed 2026-09-02 |
| 2025-12-31 | -$210.78M 6-K · filed 2026-09-02 |
| 2025-09-30 | -$205.96M 6-K · filed 2025-11-26 |
| 2025-06-30 | -$204.07M 6-K · filed 2025-08-28 |
| 2024-12-31 | -$200.47M 20-F · filed 2026-03-31 |
| 2024-06-30 | -$195.35M 6-K · filed 2024-08-28 |
| 2023-12-31 | -$192.95M 20-F · filed 2025-04-02 |
| 2023-06-30 | -$189.46M 6-K · filed 2023-08-09 |
| 2022-12-31 | -$186.04M 20-F · filed 2024-04-04 |
| 2022-06-30 | -$178.05M 6-K · filed 2022-08-04 |
| 2021-12-31 | -$168.17M 20-F · filed 2023-03-29 |
| 2021-06-30 | -$153.01M 6-K · filed 2021-08-05 |
| 2020-12-31 | -$135.71M 20-F · filed 2022-05-02 |
| 2020-06-30 | -$118.53M 6-K · filed 2020-08-06 |
| 2019-12-31 | -$106.94M 20-F · filed 2021-03-18 |
| 2019-06-30 | -$94.14M 6-K · filed 2019-08-05 |
| 2018-12-31 | -$86.47M 20-F · filed 2020-03-12 |
| 2018-06-30 | -$81.81M 6-K · filed 2018-08-02 |
| 2017-12-31 | -$76.62M 20-F · filed 2019-03-13 |
| 2017-06-30 | -$70.17M 6-K · filed 2017-07-31 |
| 2016-12-31 | -$64.32M 20-F · filed 2018-03-13 |
| 2016-06-30 | -$55.66M 6-K · filed 2017-06-23 |
| 2015-12-31 | -$47.37M 6-K · filed 2017-06-23 |
| 2014-12-31 | -$36.74M 20-F · filed 2016-03-22 |
| 2013-12-31 | -$27.64M 20-F · filed 2015-03-31 |